CRISPR Therapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 2 days.
- Its last 4 Sell calls were actually followed by a +4% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is -26.7% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 17.8% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2849 U.S. stocks StockVane covers.
Last computed: 2026-11-21 08:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D-
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | -215.0% | Better than 0% |
| Operating margin | -1,333.0% | Better than 3% |
| Net margin | -1,046.4% | Better than 2% |
| Return on equity | -30.2% | Better than 13% |
| Return on invested capital | -27.2% | Better than 11% |
Momentum D+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -34.3% | Better than 14% |
| 6-month return | -22.4% | Better than 25% |
| 12-month return (ex latest month) | -0.5% | Better than 33% |
| Distance below 52-week high | 38.4% | Better than 30% |
Financial Health B+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 13.3x | Better than 96% |
| Debt to assets | 9.1% | Better than 71% |
| Interest coverage | -1.8x | Better than 20% |
| Free cash flow / net income | 121.1% | Better than 52% |
Analyst View B+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 66.7% | Better than 41% |
| Upside to average target | 89.9% | Better than 81% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 38.93
- Open
- 38.18
- Day range
- 38.15 - 40.17
- Avg price
- 39.29
- Volume
- 3.32M
- Turnover
- 130.54M
- Turnover ratei
- 3.44%
- Volume ratioi
- 1.01
- Amplitudei
- 5.19%
- 52-week rangei
- 38.15 - 63.45
Valuation
- P/Ei
- -6.04
- P/E (TTM)i
- -8.27
- P/Bi
- 2.30
- EPSi
- -6.47
- Book value / shi
- 16.99
- Net profit
- -627.60M
- Net assets
- 1.65B
Share structure
- Market cap
- 3.79B
- Float capi
- 3.77B
- Shares out
- 97.00M
- Float sharesi
- 96.49M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2016-10-19
38.4% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-33.00M net over the window
Short interest
- Shares short
- 17.19M
- % of floati
- 17.78%
- Days to coveri
- 13.09
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of CRISPR Therapeutics (CRSP)?
CRISPR Therapeutics last traded at 39.10. This page shows a periodic quote snapshot. Check the displayed quote time.
What is CRISPR Therapeutics's market cap?
About 3.79B.
What is the P/E ratio of CRISPR Therapeutics?
The trailing twelve-month P/E is -8.27. The Valuation tab shows it against the stock's own five-year range.
Does CRISPR Therapeutics pay a dividend?
CRISPR Therapeutics does not currently pay a regular dividend.
Is CRISPR Therapeutics a buy according to analysts?
The consensus of 12 analysts is a Buy rating, with an average 12-month price target of 74.27, which implies 89.9% upside from the current price. This is not investment advice.
What is CRISPR Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates CRISPR Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 19:54:43 · For reference only, not investment advice and not tailored to your situation.
CRISPR Therapeutics discussion 0 comments